IXHL NASDAQ
Incannex NASDAQ
IXHL 2.
IXHL Partners
IXHL Market Potential
Advancements for Anxiety, Sleep Apnea, Brain Injury, Lung Inflammation, Rheumatoid Arthritis & Inflammatory Bowel Disease : Incannex Healthcare Limited
INCANNEX HEALTHCARE LIMITED (NASDAQ:IXHL)
We believe that bringing together Incannex and APIRx will bolster our position as a leader in the medicinal cannabinoid sector and will further set IHL apart from other players in the industry”— IXHL CEO Mr. Joel Latham
MELBOURNE, VICTORIA, AUSTRALIA, May 10, 2022 /EINPresswire.com/ -- Advancements for Anxiety, Sleep Apnea, Brain Injury, Lung Inflammation, Rheumatoid Arthritis & Inflammatory Bowel Disease: Incannex Healthcare Limited (NASDAQ: IXHL)
Developing Multiple Unique Cannabinoid & Psychedelic Medicine Therapies Targeted for U.S. FDA Approval and Registration.
Completed Loyalty Option Program to Raise A$23.6M Primarily Allocated to Clinical R&D Program.
Plans Underway to Acquire APIRx Pharmaceuticals USA, LLC.
Substantial Reduction in AHI in Preliminary Results of Clinical Trial Assessing IHL-42X in Patients with OSA
Incannex Healthcare Limited (NASDAQ: IXHL), is an Australian based clinical stage pharmaceutical company that is